LEPORE PATRICK G
Insider CIK 1055404 · INVA Director · PMC Director · VYNE Director · MTNB Director · LCI Director · PRX Executive Chairman, Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| VYNE VYNE Therapeutics Inc. | A Award deriv | 2025-12-12 | 2025-12-15 | 20,000 | — | $0 | 20,000 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | P Buy | 2025-01-15 | 2025-01-16 | 15,000 | $2.92 | $43.8K | 51,472 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | A Award deriv | 2024-12-12 | 2024-12-13 | 20,000 | — | $0 | 20,000 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | A Award deriv | 2024-01-01 | 2024-01-03 | 20,000 | — | $0 | 20,000 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | A Award deriv | 2023-12-13 | 2023-12-15 | 20,000 | — | $0 | 20,000 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | P Buy | 2023-11-15 | 2023-11-17 | 13,000 | $3.91 | $50.8K | 36,472 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | P Buy | 2023-03-20 | 2023-03-22 | 20,000 | $2.48 | $49.6K | 23,472 | SEC↗ |
| LCI LANNETT CO INC | P Buy | 2022-11-10 | 2022-11-14 | 100,000 | $0.49 | $49.0K | 587,145 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | A Award deriv | 2022-08-10 | 2022-08-12 | 20,500 | — | $0 | 20,500 | SEC↗ |
| LCI LANNETT CO INC | P Buy | 2022-05-16 | 2022-05-17 | 50,000 | $0.54 | $27.0K | 487,145 | SEC↗ |
| LCI LANNETT CO INC | P Buy | 2022-02-08 | 2022-02-10 | 50,000 | $0.88 | $44.0K | 437,145 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | P Buy | 2021-11-30 | 2021-12-02 | 12,500 | $1.02 | $12.8K | 62,500 | SEC↗ |
| LCI LANNETT CO INC | P Buy | 2021-11-29 | 2021-11-30 | 50,000 | $1.71 | $85.5K | 387,145 | SEC↗ |
| LCI LANNETT CO INC | P Buy | 2021-09-08 | 2021-09-09 | 20,000 | $3.31 | $66.2K | 337,145 | SEC↗ |
| LCI LANNETT CO INC | A Award | 2021-08-31 | 2021-09-02 | 56,819 | — | $0 | 317,145 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | P Buy | 2021-08-25 | 2021-08-26 | 12,500 | $1.60 | $20.0K | 50,000 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | A Award deriv | 2021-07-19 | 2021-07-20 | 20,500 | — | $0 | 20,500 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | P Buy | 2021-05-26 | 2021-05-27 | 12,500 | $3.60 | $45.0K | 37,500 | SEC↗ |
| LCI LANNETT CO INC | P Buy | 2021-05-11 | 2021-05-12 | 20,000 | $4.18 | $83.6K | 260,326 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | P Buy | 2021-03-15 | 2021-03-16 | 12,500 | $7.41 | $92.6K | 25,000 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | P Buy | 2020-12-03 | 2020-12-07 | 50,000 | $1.71 | $85.5K | 50,000 | SEC↗ |
| MTNB Matinas BioPharma Holdings | A Award deriv | 2020-11-02 | 2020-11-10 | 122,605 | — | $0 | 122,605 | SEC↗ |
| VYNE VYNE Therapeutics Inc. | A Award deriv | 2020-09-10 | 2020-09-14 | 45,000 | — | $0 | 45,000 | SEC↗ |
| LCI LANNETT CO INC | A Award | 2020-09-01 | 2020-09-03 | 38,986 | — | $0 | 240,326 | SEC↗ |
| MTNB Matinas BioPharma Holdings | P Buy | 2020-05-14 | 2020-05-18 | 100,000 | $0.73 | $73.0K | 400,000 | SEC↗ |
| MTNB Matinas BioPharma Holdings | P Buy | 2019-11-15 | 2019-11-19 | 100,000 | $1.06 | $106.0K | 300,000 | SEC↗ |
| MTNB Matinas BioPharma Holdings | A Award deriv | 2019-11-01 | 2019-11-05 | 107,416 | — | $0 | 107,416 | SEC↗ |
| LCI LANNETT CO INC | P Buy | 2019-09-03 | 2019-09-05 | 25,000 | $9.82 | $245.5K | 201,340 | SEC↗ |
| MTNB Matinas BioPharma Holdings | P Buy | 2019-08-16 | 2019-08-20 | 100,000 | $0.72 | $72.0K | 200,000 | SEC↗ |
| LCI LANNETT CO INC | A Award | 2019-07-19 | 2019-07-22 | 33,445 | — | $0 | 176,340 | SEC↗ |
| MTNB Matinas BioPharma Holdings | P Buy | 2019-05-16 | 2019-05-20 | 100,000 | $0.95 | $95.0K | 100,000 | SEC↗ |
| LCI LANNETT CO INC | P Buy | 2019-05-08 | 2019-05-09 | 25,000 | $7.32 | $183.0K | 142,895 | SEC↗ |
| LCI LANNETT CO INC | P Buy | 2019-02-12 | 2019-02-13 | 25,000 | $8.93 | $223.3K | 117,895 | SEC↗ |
| LCI LANNETT CO INC | P Buy | 2018-12-13 | 2018-12-17 | 25,000 | $5.10 | $127.5K | 92,895 | SEC↗ |
| MTNB Matinas BioPharma Holdings | A Award deriv | 2018-11-01 | 2018-11-05 | 128,299 | — | $0 | 128,299 | SEC↗ |
| MTNB Matinas BioPharma Holdings | A Award deriv | 2018-09-05 | 2018-09-06 | 150,000 | — | $0 | 150,000 | SEC↗ |
| LCI LANNETT CO INC | P Buy | 2018-08-31 | 2018-09-04 | 25,000 | $5.34 | $133.5K | 67,895 | SEC↗ |
| LCI LANNETT CO INC | A Award | 2018-07-20 | 2018-07-23 | 16,195 | — | $0 | 42,895 | SEC↗ |
| LCI LANNETT CO INC | P Buy | 2018-05-11 | 2018-05-14 | 25,000 | $15.13 | $378.3K | 26,700 | SEC↗ |
| PMC PharMerica CORP | D To issuer | 2017-12-07 | 2017-12-08 | 29,570 | $29.25 | $864.9K | 0 | SEC↗ |
| PMC PharMerica CORP | A Award | 2017-06-14 | 2017-06-16 | 4,817 | — | $0 | 29,570 | SEC↗ |
| INVA Innoviva, Inc. | A Award | 2017-04-20 | 2017-04-24 | 19,857 | — | $0 | 58,278 | SEC↗ |
| INVA Innoviva, Inc. | A Award | 2016-10-26 | 2016-10-27 | 38,421 | — | $0 | 38,421 | SEC↗ |
| PMC PharMerica CORP | A Award | 2016-06-17 | 2016-06-21 | 5,167 | — | $0 | 24,753 | SEC↗ |
| PMC PharMerica CORP | A Award | 2015-06-19 | 2015-06-23 | 3,730 | — | $0 | 19,586 | SEC↗ |
| PMC PharMerica CORP | A Award | 2014-06-17 | 2014-06-18 | 4,300 | — | $0 | 15,856 | SEC↗ |
| PMC PharMerica CORP | A Award | 2013-06-18 | 2013-07-03 | 5,556 | — | $0 | 11,556 | SEC↗ |
| PMC PharMerica CORP | A Award | 2013-06-17 | 2013-06-19 | 5,685 | — | $0 | 11,685 | SEC↗ |
| PMC PharMerica CORP | A Award | 2013-01-14 | 2013-01-14 | 6,000 | — | $0 | 6,000 | SEC↗ |
| PRX PAR PHARMACEUTICAL COMPANI | D To issuer deriv | 2012-09-28 | 2012-10-02 | 50,629 | $50.00 | $2.53M | 0 | SEC↗ |
| PRX PAR PHARMACEUTICAL COMPANI | D To issuer deriv | 2012-09-28 | 2012-10-02 | 2,500 | $50.00 | $125.0K | 0 | SEC↗ |
| PRX PAR PHARMACEUTICAL COMPANI | D To issuer deriv | 2012-09-28 | 2012-10-02 | 5,000 | $27.80 | $139.0K | 0 | SEC↗ |
| PRX PAR PHARMACEUTICAL COMPANI | D To issuer deriv | 2012-09-28 | 2012-10-02 | 65,467 | $36.94 | $2.42M | 0 | SEC↗ |
| PRX PAR PHARMACEUTICAL COMPANI | D To issuer deriv | 2012-09-28 | 2012-10-02 | 120,000 | $30.74 | $3.69M | 0 | SEC↗ |
| PRX PAR PHARMACEUTICAL COMPANI | D To issuer deriv | 2012-09-28 | 2012-10-02 | 54,132 | $22.29 | $1.21M | 0 | SEC↗ |
| PRX PAR PHARMACEUTICAL COMPANI | D To issuer deriv | 2012-09-28 | 2012-10-02 | 11,200 | $25.73 | $288.2K | 0 | SEC↗ |
| PRX PAR PHARMACEUTICAL COMPANI | D To issuer deriv | 2012-09-28 | 2012-10-02 | 120,000 | $30.00 | $3.60M | 0 | SEC↗ |
| PRX PAR PHARMACEUTICAL COMPANI | D To issuer | 2012-09-28 | 2012-10-02 | 8,000 | $50.00 | $400.0K | 0 | SEC↗ |
| PRX PAR PHARMACEUTICAL COMPANI | D To issuer | 2012-09-28 | 2012-10-02 | 15,000 | $50.00 | $750.0K | 8,000 | SEC↗ |
| PRX PAR PHARMACEUTICAL COMPANI | D To issuer | 2012-09-28 | 2012-10-02 | 65,000 | $50.00 | $3.25M | 0 | SEC↗ |
| PRX PAR PHARMACEUTICAL COMPANI | D To issuer | 2012-09-28 | 2012-10-02 | 126,792 | $50.00 | $6.34M | 65,000 | SEC↗ |
| PRX PAR PHARMACEUTICAL COMPANI | D To issuer | 2012-09-28 | 2012-10-02 | 15,000 | $50.00 | $750.0K | 0 | SEC↗ |
| PRX PAR PHARMACEUTICAL COMPANI | F Tax w/h | 2012-01-11 | 2012-01-13 | 1,652 | $35.65 | $58.9K | 191,793 | SEC↗ |
| PRX PAR PHARMACEUTICAL COMPANI | F Tax w/h | 2012-01-09 | 2012-01-11 | 5,365 | $35.09 | $188.3K | 193,445 | SEC↗ |
| PRX PAR PHARMACEUTICAL COMPANI | F Tax w/h | 2012-01-04 | 2012-01-06 | 2,941 | $32.17 | $94.6K | 198,810 | SEC↗ |